Zika Virus Testing Market to Grow with a CAGR of 6.42% through 2031F

Growing prevalence of viral diseases are expected to drive the Global Zika Virus Testing Market in the forecast period 2027-2031F

According to TechSci Research report, “Zika Virus Testing Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2031F”, the Global Zika Virus Testing Market stood at USD 169.12 Million in 2025 and is expected to reach USD 246.91 Million growing with a CAGR of 6.42% between 2027-2031.

Factors driving market growth include the increasing incidence of Zika virus infection and the rapid progress in diagnostic technologies, especially molecular and serological testing that improves early detection and public health response. WHO notes that Zika transmission persists at low levels in several countries, with continued evidence of mosquito-borne transmission in multiple endemic regions, which keeps testing demand relevant for surveillance, maternal health, and outbreak readiness. The market is also supported by stronger government action against vector-borne diseases and rising laboratory preparedness, particularly in regions where Aedes mosquitoes remain established. For Instance, Abbott developed the RealTime ZIKA assay with a limit of detection as low as 30 copies per mL in serum and 40 copies per mL in plasma and urine, while Roche launched the cobas Zika test as the first commercially available donor-screening test for Zika virus RNA.

Zika virus remains important because it is transmitted not only by Aedes mosquitoes but also through sexual contact, mother-to-fetus transmission during pregnancy, blood exposure, and organ transplantation, which broadens the need for testing beyond outbreak zones. WHO states that mosquito-transmitted Zika infection has been reported in 92 countries and territories, while surveillance remains limited in many settings, creating a gap that diagnostic testing helps fill. The persistence of transmission in the Americas and other endemic regions reinforces the need for routine detection capacity in travel medicine, prenatal care, and blood safety workflows. Asia-Pacific and South American countries have been central to past outbreaks, and the continuing presence of Aedes vectors keeps those markets strategically relevant for testing adoption.

Government-led disease control programs are also accelerating adoption of Zika diagnostics, because testing is essential to identify cases, monitor spread, and guide vector-control interventions. WHO emphasizes sustained vigilance, early detection, and development of diagnostics as core elements of preparedness, which supports procurement by public health systems and reference laboratories. In India, state and national vector-borne disease campaigns have included Zika within broader control programs, reinforcing awareness and testing readiness in endemic and at-risk districts. On the technology side, PCR-based molecular assays and automated immunoassays are improving turnaround time, sensitivity, and workflow efficiency, making them more attractive for hospitals and blood banks. For Instance, Thermo Fisher offers multiplex real-time PCR options for dengue, chikungunya, and Zika detection from a single sample, showing how multi-pathogen platforms are helping laboratories expand testing capacity.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Zika Virus Testing Market’’

The Global Zika Virus Testing Market is segmented into test type, regional distribution, and company.

Based on test type, molecular testing, especially nucleic acid amplification testing, is the fastest-growing segment in the global Zika Virus Testing Market because it delivers earlier and more reliable confirmation than symptom-based or antibody-only approaches. PCR-based methods are favored in acute infection workups, and WHO guidance supports molecular detection in whole blood, serum, plasma, and urine to improve case identification across clinical and surveillance settings. The shift toward multiplex platforms is also strengthening demand because laboratories can detect Zika alongside dengue and chikungunya from the same sample, which improves throughput and reduces operational burden. In practice, this matters most where Zika symptoms overlap with other arboviral infections, creating a real need for confirmatory testing rather than presumptive diagnosis. For Instance, Abbott’s RealTime ZIKA assay was developed for serum, plasma, urine, and whole blood, while Thermo Fisher offers multiplex real-time PCR assays for dengue, chikungunya, and Zika detection from a single workflow.

Based on region, Asia-Pacific is emerging as the fastest-growing market for Zika virus testing because the region combines recurring outbreak risk, dense mosquito habitats, and stronger public-health surveillance needs. India has been especially important, with confirmed activity reported in Kerala in July 2021 and subsequent outbreaks in states such as Maharashtra and Uttar Pradesh, showing that Zika remains a live diagnostic concern rather than a purely historical one. WHO’s broader surveillance updates also underline the need for sustained vigilance, early detection, and better laboratory preparedness in countries where Aedes vectors are established. The regional market is further supported by government response programs that expand testing capacity, strengthen vector control, and improve outbreak reporting across public laboratories. For Instance, India recorded 151 Zika cases in 2024, with Maharashtra contributing 140 cases, while a 2024 outbreak analysis identified hotspots in Uttar Pradesh, Madhya Pradesh, and Kerala.

Major companies operating in Global Zika Virus Testing Market are:

• Quest Diagnostics, Inc.
• Chembio Diagnostic Systems, Inc.
• Biocan Diagnostics, Inc.
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• SD Biosensors, Inc.

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The prevalence of Zika virus outbreaks in different regions fuels demand for early detection and monitoring. Routine testing of pregnant women in affected areas is essential due to the virus's link with severe birth defects. International travel leads to increased testing among travelers returning from Zika-affected regions. Ongoing technological advancements improve test accuracy and accessibility. Government initiatives, research, and development efforts, stringent regulatory approvals, public awareness campaigns, and global health concerns further boost the market” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Zika Virus Testing Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type (Nucleic Acid Amplification Testing (NAAT), Serological Testing), By Region & Competition. 2021-2031F”, has evaluated the future growth potential of Global Zika Virus Testing Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Zika Virus Testing Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com